DK149121B - METHOD OF PREPARING ACID ADDITION SALTS OF 3,4-DIACYLOXY-ALFA - ((METHYLAMINO) -METHYL) -BENZYL ALCOHOL - Google Patents
METHOD OF PREPARING ACID ADDITION SALTS OF 3,4-DIACYLOXY-ALFA - ((METHYLAMINO) -METHYL) -BENZYL ALCOHOL Download PDFInfo
- Publication number
- DK149121B DK149121B DK24082A DK24082A DK149121B DK 149121 B DK149121 B DK 149121B DK 24082 A DK24082 A DK 24082A DK 24082 A DK24082 A DK 24082A DK 149121 B DK149121 B DK 149121B
- Authority
- DK
- Denmark
- Prior art keywords
- acid addition
- methylamino
- methyl
- diacyloxy
- alfa
- Prior art date
Links
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
i 149121in 149121
Den foreliggende opfindelse angår en fremgangsmåde til fremstilling og isolering af en 3,4-diaGyloxy-a-[(methylamino)-methyl]-benzylalkohol med formlen o 5 hvori R betyder alkyl eller aralkyl, i form af et syreadditionssalt.The present invention relates to a process for preparing and isolating a 3,4-diaGyloxy-α - [(methylamino) methyl] benzyl alcohol of the formula o wherein R is alkyl or aralkyl, in the form of an acid addition salt.
De ved fremgangsmåden ifølge opfindelsen fremstillede forbindelser er kendte forbindelser med sympatomimetiske egenskaber, og de har med godt resultat været anvendt bl.a. til 10 behandling af glaucoma. Forbindelsernes langvarige virkning sammenlignet med den tilsvarende 3,4-dihydroxy-forbindelse, dvs. adrenalin, skyldes ifølge litteraturen O-acyl-beskytteisen, som i tilfælde af adrenalin forhindrer, at der i organismen sker en meget hurtig oxidation til forbindelser, som 15 ikke har nogen virkning.The compounds prepared by the process according to the invention are known compounds with sympathomimetic properties and have been used with good results, among other things. for 10 treatment of glaucoma. The long-lasting effect of the compounds compared to the corresponding 3,4-dihydroxy compound, i.e. According to the literature, the adrenaline is due to the O-acyl protective ice, which in the case of adrenaline prevents a very rapid oxidation in the organism to compounds which have no effect.
Uanset beskyttelsen af de reaktive grupper er acylforbindel-serne med formlen I ikke stabile under basiske betingelser, da hydrolysen af acyloxygrupperne straks efterfølges af dannelsen af oxidationsprodukter. I sure opløsninger er for-20 bindeiserne imidlertid rimeligt stabile. Af de ovenfor anførte årsager kan aminerne med formlen I ikke isoleres ved anvendelse af konventionelle fremgangsmåder til fremstilling af aminer.Notwithstanding the protection of the reactive groups, the acyl compounds of formula I are not stable under basic conditions since the hydrolysis of the acyloxy groups is immediately followed by the formation of oxidation products. However, in acidic solutions the precursors are reasonably stable. For the reasons stated above, the amines of formula I cannot be isolated using conventional processes for the preparation of amines.
Ifølge de i litteraturen beskrevne fremgangsmåder til frem-25 stilling af forbindelserne med formlen I behandles 0-diacyle-de catecholaminer som salte i opløsningsmidler af alkoholtypen, såsom methanol eller ethanol, hvorved ovennævnte ufordelagtige fænomen ikke optræder. Fra beskrivelsen til US-pa- 149121 2 tent nr. 3.809.714 og nr. 4.035.405 er det kendt at fremstille en sådan forbindelse ud fra hydrochloridsaltet af en forbindelse indeholdende en ketofunktion, og som har formlen ! -According to the methods described in the literature for the preparation of the compounds of formula I, O-diacylated catecholamines are treated as salts in alcohol-type solvents such as methanol or ethanol, whereby the above-mentioned disadvantageous phenomenon does not occur. From the disclosure of U.S. Patent Nos. 3,809,714 and 4,035,405, it is known to prepare such a compound from the hydrochloride salt of a compound containing a keto function and having the formula! -
R-C-0 OR-C-0 O
5 R-C-O- /7 S>-C-CH0-NH-CH0 (li) I 2 35 R-C-O- / 7 S> -C-CHO-NH-CHO (li) I 2 3
OISLAND
hvori R har den ovenfor angivne betydning, ved katalytisk hydrogenering under tryk i methanol eller ethanol i nærværelse af en platinoxidkatalysator. Produktet isoleres på konventionel måde ved filtrering af katalysatoren fra re-10 aktionsblandingen, fordampning af opløsningsmidlet og krystallisering af forbindelsen med formlen I som et produkt fra en passende opløsningsmiddelblanding.wherein R is as defined above by catalytic hydrogenation under pressure in methanol or ethanol in the presence of a platinum oxide catalyst. The product is isolated in a conventional manner by filtration of the catalyst from the reaction mixture, evaporation of the solvent and crystallization of the compound of formula I as a product of a suitable solvent mixture.
Ifølge beskrivelsen til FI-patent nr. 55.988 fremstilles forbindelsen med formlen I ved at reducere en forbindelse 15 med formlenAccording to the disclosure of FI Patent No. 55,988, the compound of formula I is prepared by reducing a compound 15 of formula
OISLAND
|| _ R-C-0 O CH V (III) >-v 11 1 R-C-O- X-C-CH2-N-CH3|| _ R-C-0 O CH V (III)> -v 11 1 R-C-O- X-C-CH 2 -N-CH 3
OISLAND
hvori R har den ovenfor angivne betydning, ved hjælp af katalytisk hydrogenering i et vandigt opløsningsmiddel under anvendelse af palladium på aktivt trækul som katalysa-20 tor.wherein R is as defined above by catalytic hydrogenation in an aqueous solvent using palladium on activated charcoal as a catalyst.
Disse kendte fremgangsmåder er imidlertid besværlige, da katalytisk hydrogenering kræver anvendelse af trykbeholdere. Endvidere er der altid en væsentlig risiko for selvantændelse forbundet med katalysatisk hydrogenering.However, these known methods are cumbersome as catalytic hydrogenation requires the use of pressure vessels. Furthermore, there is always a significant risk of self-ignition associated with catalytic hydrogenation.
25 Fremgangsmåden ifølge opfindelsen til fremstilling af forbindelserne med formlen I er ejendommelig ved, at et syre- 3 149121 additionssalt af den tilsvarende amin indeholdende en keto-funktion og med formlenThe process of the invention for preparing the compounds of formula I is characterized in that an acid addition salt of the corresponding amine containing a keto function and of the formula
R-c-°v_ IR-c- ° v_ I
R—o— -C-CH2-NH-CH2 (II) o hvori R har den ovenfor angivne betydning, opløst i en sy-5 re, fortrinsvis eddikesyre, reduceres med natrium- eller ka-liumborhydrid, hvorefter der sættes vand til reaktionsblandingen, den vandige blanding ekstraheres med et chloreret carbonhydrid, hvorpå der sættes syre til den chlorerede car-bonhydridfase, og syreadditionssaltet isoleres.Wherein R is as defined above, dissolved in an acid, preferably acetic acid, is reduced with sodium or potassium borohydride and then water is added to the reaction mixture , the aqueous mixture is extracted with a chlorinated hydrocarbon, then acid is added to the chlorinated hydrocarbon phase and the acid addition salt is isolated.
10 Reduktionen i overensstemmelse med fremgangsmåden ifølge opfindelsen kan let gennemføres under normale betingelser og under anvendelse af almindelige reaktionsbeholdere, hvorved man undgår ulemperne i forbindelse med ovennævnte katalytiske hydrogenering.The reduction in accordance with the process of the invention can be easily carried out under normal conditions and using ordinary reaction vessels, thereby avoiding the disadvantages of the above catalytic hydrogenation.
15 Reduktionsmidlets reducerende virkning afhænger af opløsningsmidlet, og det er derfor vigtigt at vælge et rigtigt opløsningsmiddel til reaktionen. Iseddike har vist sig at være et særdeles fordelagtigt opløsningsmiddel.The reducing effect of the reducing agent depends on the solvent and it is therefore important to choose the right solvent for the reaction. Ice vinegar has proven to be a particularly advantageous solvent.
Reaktionsproduktet kan let ekstraheres fra den vandige op-20 løsning med chlorerede carbonhydrider, såsom chloroform eller methylenchlorid. Produktets opløselighed i chlorerede carbonhydrider er jo bedre, desto større gruppen R er.The reaction product can be easily extracted from the aqueous solution with chlorinated hydrocarbons such as chloroform or methylene chloride. The better the solubility of the product in chlorinated hydrocarbons, the larger the group R is.
Ifølge en fordelagtig udførelsesform for fremgangsmåden ifølge opfindelsen fremstilles forbindelsen med formlen I 25 ved at opløse hydrochloridsaltet af aminen med formlen II i eddikesyre og at reducere med natriumborhydrid ved en temperatur på fra 0 til 50°C og en reaktionstid på fra 1 til 2 149121 4 timer. Det er særlig fordelagtigt at gennemføre omsætningen ved eller under stuetemperatur (fra 0 til 25°C), hvorved den eksoterme reaktion kræver afkøling.According to an advantageous embodiment of the process according to the invention, the compound of formula I 25 is prepared by dissolving the hydrochloride salt of the amine of formula II in acetic acid and reducing with sodium borohydride at a temperature of from 0 to 50 ° C and a reaction time of from 1 to 2. hours. It is particularly advantageous to carry out the reaction at or below room temperature (from 0 to 25 ° C), whereby the exothermic reaction requires cooling.
Reaktionsproduktet isoleres ved at sætte vand til reaktions-5 blandingen, hvorefter det ekstraheres, f.eks. med chloroform.The reaction product is isolated by adding water to the reaction mixture and then extracted, e.g. with chloroform.
Al eventuel medekstraheret eddikesyre fjernes fra chloroformfasen ved vask, f.eks. med en natriumhydrogencarbonatopløsning, hvorefter chloroformfasen behandles med fortyndet saltsyre. Efter fordampning af chloroformet fås som remanens 10 hydrochloridet af forbindelsen med formlen I, som kan krystalliseres fra en passende opløsningsmiddelblanding.Any co-extracted acetic acid is removed from the chloroform phase by washing, e.g. with a sodium hydrogen carbonate solution, after which the chloroform phase is treated with dilute hydrochloric acid. After evaporation of the chloroform, the hydrochloride of the compound of formula I is obtained as the residue 10, which can be crystallized from a suitable solvent mixture.
Udgangsforbindelsen med formlen II kan fremstilles ud fra adrenalon på i og for sig kendt måde, f.eks. som anført i beskrivelsen til US-patent nr. 3.809.714 og nr. 4.035.405.The starting compound of formula II can be prepared from adrenalone in a manner known per se, e.g. as disclosed in U.S. Patent Nos. 3,809,714 and 4,035,405.
15 Fremgangsmåden ifølge opfindelsen illustreres i det følgende eksempel.The process of the invention is illustrated in the following example.
7,7 g (0,02 mol) dipivaloyladrenalon-hydrochlorid opløses ved stuetemperatur i 50 ml eddikesyre. Til reaktionsblandingen sættes under afkøling og omrøring i løbet af en halv 20 time 2,5 g natriumborhydrid. Reaktionsblandingen omrøres på et is-vandbad i yderligere 1 time, hvorefter blandingen omhyggeligt tilsættes 150 ml vand. Omsætningen kan følges ved hjælp af tyndtlagskromatografering under anvendelse af en 12:3:1-blanding af CH^-MK^, isopropanol og NH^ (95%·s).Dissolve 7.7 g (0.02 mol) of dipivaloyladrenalone hydrochloride at room temperature in 50 ml of acetic acid. To the reaction mixture is added 2.5 g of sodium borohydride during cooling and stirring for half an hour. The reaction mixture is stirred on an ice-water bath for an additional 1 hour, after which time the mixture is carefully added 150 ml of water. The reaction can be followed by thin layer chromatography using a 12: 3: 1 mixture of CH 2 -MK 2, isopropanol and NH 2 (95% s).
25 Den vandige opløsningen ekstraheres med 3 gange 50 ml chlo·«-roform, hvorefter chloroformopløsningen vaskes med 50 ml koncentreret natriumhydrogencarbonatopløsning, 50 ml 2 N saltsyre og 50 ml vand. Chloroformopløsningen tørres og inddampes til tørhed, og remanensen på 7,0 g krystallise-30 res fra en blanding af acetone og hexan. Udbytte: 5,5 g (71%) dipivaloyl-adrenalin-hydrochlorid med smp. 158,5-160°C (litteratur 159-160°C) og en renhed på 99,9% bestemt titremetrisk.The aqueous solution is extracted with three times 50 ml of chloroform, after which the chloroform solution is washed with 50 ml of concentrated sodium bicarbonate solution, 50 ml of 2N hydrochloric acid and 50 ml of water. The chloroform solution is dried and evaporated to dryness and the residue of 7.0 g is crystallized from a mixture of acetone and hexane. Yield: 5.5 g (71%) of dipivaloyl-adrenaline hydrochloride, m.p. 158.5-160 ° C (literature 159-160 ° C) and a purity of 99.9% determined titremetrically.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI810700 | 1981-03-06 | ||
FI810700A FI61474C (en) | 1981-03-06 | 1981-03-06 | FAR OIL FRAMSTAELLNING AV SYRAADDITIONSSALTER AV 3,4-DIACYLOXI-ALPHA - ((METHYLAMINO) -METHYL) -BENYL ALCOHOL |
Publications (3)
Publication Number | Publication Date |
---|---|
DK24082A DK24082A (en) | 1982-09-07 |
DK149121B true DK149121B (en) | 1986-02-03 |
DK149121C DK149121C (en) | 1986-07-07 |
Family
ID=8514202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK24082A DK149121C (en) | 1981-03-06 | 1982-01-20 | METHOD OF PREPARING ACID ADDITION SALTS OF 3,4-DIACYLOXY-ALFA - ((METHYLAMINO) -METHYL) -BENZYL ALCOHOL |
Country Status (15)
Country | Link |
---|---|
AT (1) | AT380684B (en) |
CA (1) | CA1178605A (en) |
CS (1) | CS229927B2 (en) |
DD (1) | DD202424A5 (en) |
DK (1) | DK149121C (en) |
ES (1) | ES8301891A1 (en) |
FI (1) | FI61474C (en) |
GR (1) | GR76375B (en) |
HU (1) | HU186483B (en) |
IT (1) | IT8219944A0 (en) |
NO (1) | NO151704C (en) |
PL (1) | PL235313A1 (en) |
PT (1) | PT74540B (en) |
RO (1) | RO84817B (en) |
SU (1) | SU1122219A3 (en) |
-
1981
- 1981-03-06 FI FI810700A patent/FI61474C/en not_active IP Right Cessation
-
1982
- 1982-01-13 AT AT0009182A patent/AT380684B/en not_active IP Right Cessation
- 1982-01-20 DK DK24082A patent/DK149121C/en not_active IP Right Cessation
- 1982-01-29 ES ES509170A patent/ES8301891A1/en not_active Expired
- 1982-02-01 CA CA000395336A patent/CA1178605A/en not_active Expired
- 1982-02-24 CS CS127882A patent/CS229927B2/en unknown
- 1982-03-01 DD DD23779582A patent/DD202424A5/en not_active IP Right Cessation
- 1982-03-03 IT IT8219944A patent/IT8219944A0/en unknown
- 1982-03-04 PL PL23531382A patent/PL235313A1/xx unknown
- 1982-03-04 RO RO106810A patent/RO84817B/en unknown
- 1982-03-05 SU SU823402587A patent/SU1122219A3/en active
- 1982-03-05 PT PT7454082A patent/PT74540B/en unknown
- 1982-03-05 NO NO820691A patent/NO151704C/en unknown
- 1982-03-05 HU HU68282A patent/HU186483B/en not_active IP Right Cessation
- 1982-09-26 GR GR67430A patent/GR76375B/el unknown
Also Published As
Publication number | Publication date |
---|---|
NO820691L (en) | 1982-09-07 |
HU186483B (en) | 1985-08-28 |
FI61474B (en) | 1982-04-30 |
GR76375B (en) | 1984-08-06 |
AT380684B (en) | 1986-06-25 |
CA1178605A (en) | 1984-11-27 |
RO84817B (en) | 1984-10-30 |
PL235313A1 (en) | 1982-09-27 |
ATA9182A (en) | 1985-11-15 |
PT74540B (en) | 1986-01-27 |
DK149121C (en) | 1986-07-07 |
DD202424A5 (en) | 1983-09-14 |
NO151704C (en) | 1985-05-22 |
NO151704B (en) | 1985-02-11 |
FI61474C (en) | 1982-08-10 |
ES509170A0 (en) | 1982-12-16 |
CS229927B2 (en) | 1984-07-16 |
DK24082A (en) | 1982-09-07 |
IT8219944A0 (en) | 1982-03-03 |
SU1122219A3 (en) | 1984-10-30 |
ES8301891A1 (en) | 1982-12-16 |
RO84817A (en) | 1984-09-29 |
PT74540A (en) | 1982-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dakin et al. | A general reaction of amino acids | |
IE930475A1 (en) | Process for the preparation of¹N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine¹and acid addition salts thereof | |
WO2013008247A1 (en) | Process for preparation of (dl) -norepinephrine acid addition salt, a key intermediate of (r) - (-) - norepinephrine | |
JPS6317832B2 (en) | ||
EP0208948B1 (en) | A method for optical resolution of phenylacetic acid derivative | |
US4002666A (en) | Process for the preparation of optically active p-hydroxyphenylglycine | |
DK149121B (en) | METHOD OF PREPARING ACID ADDITION SALTS OF 3,4-DIACYLOXY-ALFA - ((METHYLAMINO) -METHYL) -BENZYL ALCOHOL | |
US2393820A (en) | Methylaminomethyl-(3-amino-4-hydroxy-phenyl)-carbinol and salts thereof | |
SU535899A3 (en) | The method of obtaining - (1-bisarylalkylaminoalkyl) -aralkoxybenzyl alcohols or their salts, racemates or optically active antipodes | |
JPS58172344A (en) | Manufacture of phenylalkanoic acid | |
NL193184C (en) | Process for preparing azonia spironortropanol esters and pharmaceutical preparation containing such an ester. | |
US4226803A (en) | Process for production of optically active bases | |
JPS6053039B2 (en) | N-Acetyl/Iramic acid derivative and method for producing the same | |
Davies et al. | Amines Related to Epinephrine. IV. Some γ-Aryl, γ-Hydroxypropyl Amines and Intermediate β-Aminopropiophenones | |
US2485116A (en) | Synthesis of dl-methionine | |
NZ201412A (en) | Preparation of 4-aminobutyramide | |
KR800001699B1 (en) | Process for the preparation of amino-phenyl-ethanol amine | |
JPS622570B2 (en) | ||
JPS61172846A (en) | Method of optical resolution of (+-)-2-chloroprorionic acid | |
US2806852A (en) | Process fgh preparing j-pyridinols | |
SU300990A1 (en) | ||
SU516684A1 (en) | Metals-containing cholesterol ester derivatives of chloroic acid | |
PL86679B1 (en) | ||
DD143249A1 (en) | PROCESS FOR PREPARING 2-SUBSTITUTED 1- (2,6-D | |
JPS62111952A (en) | Production of (2-(4-acetoxy-2-isopropyl-5-methylphenoxy)-ethyl)-dimethylamine) hydrochloride |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PBP | Patent lapsed |